New drug shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT03580564
First seen May 07, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappeared. The study also tracked how long any response lasted and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KL-A167 (a drug given intravenously every two weeks)
What this could lead to
If successful, this could offer a new treatment option for people with Hodgkin lymphoma that has not responded to other therapies.
What could go wrong
This is a mid-stage trial with only 109 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors in some patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.